India's pharmaceutical exports reached $27.9 billion in FY2025, making it the world's third-largest pharmaceutical producer by volume. Here are the top therapeutic categories driving this growth.
1. Anti-Infectives (Antibiotics & Antimicrobials)
Anti-infectives remain the largest segment of Indian pharma exports, accounting for approximately 18-20% of total exports. India is the world's leading producer of generic antibiotics including amoxicillin, azithromycin, ciprofloxacin, and cephalosporins.
Key drivers: rising antimicrobial resistance necessitating newer combinations, strong demand from African and Southeast Asian markets, and competitive pricing for WHO-prequalified products.
2. Cardiovascular Medicines
Cardiovascular drugs represent about 12-14% of Indian pharma exports. Top exports include statins (atorvastatin, rosuvastatin), antihypertensives (amlodipine, losartan, telmisartan), and antiplatelet agents (clopidogrel).
The global cardiovascular disease burden continues to grow, with hypertension affecting over 1.2 billion adults worldwide. Indian generic versions typically cost 80-90% less than branded originals.
3. Anti-Diabetic Medications
With the global diabetes population exceeding 530 million, anti-diabetic drugs constitute approximately 10-12% of Indian pharma exports. Leading products include metformin, glimepiride, sitagliptin, and the rapidly growing SGLT2 inhibitor class (empagliflozin, dapagliflozin).
4. Oncology Products
Oncology is the fastest-growing export segment, growing at 15-18% annually. India has become a major source for generic targeted therapies (imatinib, erlotinib, sorafenib), hormonal therapies (tamoxifen, letrozole), and chemotherapy agents (capecitabine, gemcitabine).
The cost savings are dramatic: imatinib (Gleevec), which costs $70,000+/year in the US, is available as a quality Indian generic for under $1,000/year.
5. Gastroenterology
Proton pump inhibitors (pantoprazole, omeprazole, esomeprazole) and antiemetics (ondansetron) are major export categories. India is the world's largest producer of PPIs, supplying both finished dosages and active pharmaceutical ingredients (APIs) globally.
6. Pain Management & NSAIDs
Non-steroidal anti-inflammatory drugs and analgesics — including diclofenac, ibuprofen, paracetamol, and gabapentinoids (pregabalin) — represent a significant export category. India supplies both formulations and APIs for these widely-used medications.
7. Antivirals
India's antiviral exports surged post-2020 and remain strong, driven by HIV/AIDS treatment (tenofovir, emtricitabine, dolutegravir), hepatitis C (sofosbuvir, daclatasvir), and hepatitis B medications. India supplies over 80% of the global HIV treatment market through organisations like the Global Fund and PEPFAR.
8. Dermatology Products
Topical formulations for skin conditions — including antifungals (terbinafine, clotrimazole), retinoids (tretinoin), corticosteroids (betamethasone), and anti-acne treatments — are growing export segments. Indian manufacturers have particular strength in cream, gel, and ointment formulations.
9. Respiratory & Allergy
Inhalers (salbutamol, budesonide, formoterol combinations), antihistamines (cetirizine, fexofenadine), and leukotriene antagonists (montelukast) are key respiratory exports. India is developing capabilities in complex inhaler delivery devices that were previously dominated by Western manufacturers.
10. Nutritional Supplements & Nutraceuticals
The fastest-growing non-Rx segment includes multivitamins, iron supplements, calcium with vitamin D3 formulations, and specialty nutraceuticals. This category benefits from lower regulatory barriers in many importing countries.
NexCure Health's Category Coverage
NexCure Health maintains an extensive product catalogue spanning all 10 of these therapeutic categories, with particular strength in anti-infectives, cardiovascular, oncology, and nutritional supplements.